Dublin, Ireland, 24 January 2022.

Biosyn Arzneimittel GmbH and Kora Healthcare concluded an exclusive licensing agreement for the continued supply and commercialisation of selenase ® (sodium selenite pentahydrate) in the United Kingdom for the treatment of a proven selenium deficiency that cannot be offset from food sources. Following marketing authorisation in 2004, Biosyn AG has acted as the marketing authorisation holder for selenase® with a local UK distributor in place. However, effective from February 1st, 2022, Kora Healthcare will assume responsibilities for the marketing and distribution of selenase ® in the United Kingdom as marketing authorisation holder.

Andreas Meyer, Chief Executive Officer of Biosyn Arzneimittel GmbH, comments:

”As a result of Brexit -related regulatory changes in the UK market, we have been intensely searching for a new partner to further develop our UK business. We are delighted to have found the ideal partner in Kora Healthcare, a company with vast expertise in the field and goals as ambitious as ours. Through our joint collaboration we plan to address selenium deficiency, which is an underestimated phenomenon in Europe and in the UK in particular”.

Conor O’Daly, Chief Executive Officer of Kora Healthcare, adds:

“This novel and first-to-market treatment for selenium deficiency complements and strengthens our UK product portfolio offering. Our well-established UK infrastructure across existing therapeutics areas of interest allows Kora to on-board a ready-to-market product like selenase ® across the many applicable patient pathways and treatment regimens”.

About selenase ®: selenase ® (Sodium selenite pentahydrate) is available both as a solution for injection and an oral solution and is indicated for proven selenium deficiency that cannot be offset from food sources. Selenase ® has been used by healthcare professionals in the UK since 2004 across a variety of clinical settings where selenium deficiency can occur including intensive care settings, oncology, gynaecology, and others. Each selenase ® product presentation is available through any UK full-line wholesaler. Selenase ® is approved in 27 countries.

About Kora Healthcare: Kora Healthcare, a subsidiary of Immdal Limited, is a privately owned healthcare and pharmaceutical company headquartered in the Republic of Ireland. Kora Healthcare is a fully integrated healthcare company with core competencies across Research, Development & Innovation, Scientific & Medical Affairs, Regulatory Affairs & Pharmacovigilance, Quality, Supply Chain, Marketing & Sales, Finance and Customer Services. All departments are led from their headquarters in Dublin, Ireland with UK sales and marketing operations located in York, UK and North American sales and marketing operations located in Toronto, Canada. Strategically committed to on-going growth and development, Kora Healthcare is actively engaged in licensing, partnering, developing and marketing of specialty prescription pharmaceuticals and consumer healthcare products.

About biosyn GmbH: biosyn Arzneimittel GmbH is a pharmaceutical and biotech company based in Fellbach, Germany. It specialises in trace elements, is a world leader for high-dose selenium injections, developer and operator of two unique cGMP manufacturing operations for producing active ingredients, and in the biotech sector, is actively involved in the production of glyco-protein isolated from the Megathura crenulata, a sea snail found in California. 70 percent of biosyn’ s sales turnover is realised outside of Germany – in 27 countries all around the world.

With products geared to the areas of intensive care, oncology and endocrinology, biosyn is a partner to hospitals and physicians in private practice, as well as to naturopathic physicians and holistic health practitioners. The company pursues in-house research and development and constantly extends its network of national and international partners. As a mid-sized family enterprise, biosyn places great value on an open, engaged and customer-oriented corporate culture.

For further information about selenase ®, please see the link to the Summary of Product Characteristics



Kora Healthcare

Tel.: +353 (0)1 8900406